Rare Neuromuscular Disorders
Clinical research activity includes thymidine kinase 2 deficiency, with interest in therapies for inherited conditions that affect muscle function and cellular energy metabolism.
- Thymidine kinase 2 deficiency
- Inherited myopathy
- Mitochondrial disease
Work in this area centers on treatment options for patients with persistent neuromuscular impairment and related rare disease manifestations.
Developmental and Epileptic Encephalopathies
The sponsor supports studies in Dravet syndrome, reflecting a therapeutic focus on severe childhood-onset epileptic disorders with developmental consequences.
- Dravet syndrome
- Early-onset epilepsy
- Seizure control
Research interest extends to treatment approaches for infants and young children living with drug-resistant seizures and associated neurodevelopmental challenges.
Neurodevelopmental Disorders
Clinical trials also address Rett syndrome, with emphasis on conditions that combine neurological impairment, developmental regression, and complex functional needs.
- Rett syndrome
- Neurodevelopmental disability
- Motor and communication impairment
This area includes therapeutic interest in symptoms that affect movement, cognition, and day-to-day functioning in individuals with rare genetic neurodevelopmental disease.
Rare Disease Therapeutics
The sponsor’s portfolio spans orphan disease research with attention to treatments for genetically defined conditions affecting the nervous system and muscle.
- Orphan drug development
- Genetic disorders
- Pediatric rare disease
Its clinical research landscape reflects sustained involvement in specialty therapeutic areas where unmet medical need remains high.
